DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH

Sauter, Guido; Gasser, Thomas C.; Moch, Holger; Richter, Jan; Jiang, Feng; Albrecht, R.; Novotny, Hedvika; Wagner, Urs; Bubendorf, Lukas; Mihatsch, Michael J.

doi:10.1007/bf00942046

Cited by 45 publications

(21 citation statements)

References 17 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…14,36 However, there is a point of diminishing returns at which the inclusion of additional probes does not provide significant increases in the overall sensitivity of the assay. 36 Furthermore, it is currently not possible to have more than four different visually distinguishable fluorophores in a single FISH probe set due to spectral overlap in the excitation and emission spectra of the different fluorescent labels. Because the goal of this study was to identify a four-probe set that would provide optimal sensitivity and specificity for the detection of dysplasia and esophageal adenocarcinoma in patients with Barrett's esophagus, ROC curves for various fourprobe combinations were performed.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Development of a Fluorescence in Situ Hybridization Assay for the Detection of Dysplasia and Adenocarcinoma in Barrett's Esophagus

Brankley

Wang

Harwood

et al. 2006

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

The goal of this study was to identify a set of fluorescence in situ hybridization probes for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. We examined 170 brushing specimens from 138 patients with Barrett's esophagus or a history of Barrett's esophagus using fluorescence in situ hybridization with probes to 5p15, 5q21-22, centromere 7, 7p12, 8q24.12-13, centromere 9, 9p21, centromere 17, 17p13.1, 17q11.2-12, 20q13.2, and centromere Y. Receiver-operator curves were used to determine the sensitivity and specificity of various four-probe combinations for detecting low-grade dysplasia, high-grade dysplasia, and esophageal adenocarcinoma. Endoscopic biopsy results were used as the gold standard. Numerous four-probe combinations provided a similarly high sensitivity and specificity. Of these, a set consisting of probes to 8q24, 9p21, 17q11.2, and 20q13.2 was found to have a sensitivity and specificity, respectively, of 70% and 89% for low-grade dysplasia, 84% and 93% for high-grade dysplasia, and 94% and 93% for esophageal adenocarcinoma. This probe set was chosen for future prospective clinical evaluations based on its high sensitivity and specificity, its ability to distinguish adenocarcinoma and high-grade or low-grade dysplasia from lesser diagnostic categories, and the favorable signal quality for each of the probes. The majority of esophageal adenocarcinomas is thought to arise in patients with Barrett's esophagus. Barrett's esophagus is a preneoplastic condition caused by metaplasia of the normal squamous mucosa of the distal esophagus into specialized intestinal mucosa containing goblet cells.1 Individuals with Barrett's esophagus have a 30-to 60-fold elevated risk of developing adenocarcinoma and develop adenocarcinoma at a rate of ϳ0.5 to 1.0% per year of follow-up. 2-5The American College of Gastroenterology has recommended that Barrett's esophagus patients be monitored for the development of dysplasia and adenocarcinoma by undergoing regular endoscopic examinations of the esophagus and obtaining four-quadrant biopsies for every 1 to 2 cm of affected esophagus.6,7 However, there are problems associated with the use of biopsies for monitoring Barrett's esophagus patients for the development of neoplasia including: 1) limited sampling of the affected mucosa leading to false-negative biopsy results, 8 2) lengthy procedure time required to take fourquadrant biopsies every 1 to 2 cm, 7 3) poor interobserver reproducibility of pathologists for the diagnosis of dysplasia, 9 and 4) relatively poor ability of histological findings to predict which patients are likely to progress to adenocarcinoma.10 Assays that improve the ability to accurately detect dysplasia and esophageal adenocarcinoma as well as predict which patients will progress to adenocarcinoma could markedly improve the clinical management of these patients. Conventional cytology is not routinely performed on endoscopic brushings obtained from patients with Barrett's esophagus in most institutions, and there are rel...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The Development of a Fluorescence in Situ Hybridization Assay for the Detection of Dysplasia and Adenocarcinoma in Barrett's Esophagus

Brankley

Wang

Harwood

et al. 2006

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

show abstract

“…For the slides prepared from adjacent normal-appearing bronchial tissue, only those uncontaminated by tumor cells were processed for further FISH analysis. Dualcolor FISH was done using a digoxigenin-labeled SP-A probe as described by our previous publication (29), and a CEP10 was used as an internal reference.…”

Section: Methodsmentioning

confidence: 99%

Surfactant Protein A Gene Deletion and Prognostics for Patients with Stage I Non–Small Cell Lung Cancer

Jiang¹,

Caraway²,

Bekele

et al. 2005

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: The present study was conducted to determine clinical relevance of surfactant protein A (SP-A) genetic aberrations in early-stage non^small cell lung cancer (NSCLC). Experimental Design: To determine whether SP-A aberrations are lung cancer^specific and indicate smoking-related damage, tricolor fluorescence in situ hybridization with SP-A and PTEN probes was done on touch imprints from the lung tumors obtained prospectively from 28 patients with primary NSCLC. To further define the clinical relevance of SP-A aberrations, fluorescence in situ hybridization was done on both tumor cells and adjacent bronchial tissue cells from paraffin-embeddedtissueblocksfrom130 patientsNSCLC for whomwehadfollow-upinformation. Results: SP-A was deleted from 89% of cancer tissues and the deletion was related to the smoking status of patients (P < 0.001). PTEN was deleted from 16% in the cancer tissues and the deletion was not related to the smoking status of patients (P > 0.05). In the cells isolated from paraffin-embedded tissue blocks, SP-A was deleted from 87% of the carcinoma tissues and 32% of the adjacent normal-appearing bronchial tissues. SP-A deletions in tumors and adjacent normal-appearing bronchial tissues were associated with increases in the risk of disease relapse (P = 0.0035 and P < 0.001, respectively). SP-A deletions in the bronchial epithelium were the strongest prognostic indicators of disease-specific survival (P = 0.025). Conclusions: Deletions of the SP-A gene are specific genomic aberrations in bronchial epithelial cells adjacent to and within NSCLC, and are associated with tumor progression and a history of smoking. SP-A deletions might be a useful biomarker to identify poor prognoses in patients with NSCLC who might therefore benefit from adjuvant treatment.

show abstract

“…Studies have shown that fluorescently labeled probes of chromosomes 3, 7, 17 and 9 could detect bladder UC as a non-invasive and sensitive test [5,6,7,9,10,14,15,16,17,18,19,20,21,22]. To date, few groups reported their studies on the utility of FISH in the detection of UUT-UC [23,24,25].…”

Section: Discussionmentioning

confidence: 99%

Distinguishing Urothelial Carcinoma in the Upper Urinary Tract from Benign Diseases with Hematuria Using FISH

Wang

Wu²,

Peng³

et al. 2012

Acta Cytologica

View full text Add to dashboard Cite

Objective: The aims of this study were to evaluate the clinical utility of a fluorescence in situ hybridization (FISH) assay as a non-invasive molecular test to distinguish urothelial carcinoma (UC) in the upper urinary tract (UUT) from benign lesions presenting with hematuria. Study Design: The chromosomal abnormalities of chromosomes 3, 7, 17 and 9 (p16) in hematuria specimens from 34 patients with UUT-UC and 33 patients with benign disorders were detected using a set of fluorescently labeled DNA probes. The abnormalities of the chromosomes were determined and analyzed between UUT-UC and benign disorders. Results: Chromosomal abnormalities were detected in 25 of 34 (73.5%) patients with UUT-UC and in 2 of 33 (6.1%) patients with benign disorders (p < 0.001). Conclusions: FISH of chromosomes 3, 7, 9 and 17 performed on exfoliated cells from voided urine specimens may serve as a non-invasive tool to distinguish UUT-UC from benign disorders presenting with hematuria.

show abstract

DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH

Cited by 45 publications

References 17 publications

The Development of a Fluorescence in Situ Hybridization Assay for the Detection of Dysplasia and Adenocarcinoma in Barrett's Esophagus

The Development of a Fluorescence in Situ Hybridization Assay for the Detection of Dysplasia and Adenocarcinoma in Barrett's Esophagus

Surfactant Protein A Gene Deletion and Prognostics for Patients with Stage I Non–Small Cell Lung Cancer

Distinguishing Urothelial Carcinoma in the Upper Urinary Tract from Benign Diseases with Hematuria Using FISH

Contact Info

Product

Resources

About